Drugs / PTX-200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02930109 | Dec 2016 → Oct 2023 | acute leukemia | Prescient Therapeutics, Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTX-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02930109 ↗ |
| Route | Intravenous | “PTX-200 will be administered as an intravenous infusion on Day 1 each cycle.” NCT02930109 ↗ |